A
Aevi Genomic Medicine
Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies
About Aevi Genomic Medicine
Aevigenomics is a pioneering startup in the biotechnology sector, focusing on advanced genomic solutions. The company leverages cutting-edge technology to analyze and interpret genetic data, providing actionable insights for personalized healthcare. Aevigenomics primarily serves healthcare providers, research institutions, and pharmaceutical companies. These clients use the company's genomic data to develop targeted treatments, conduct research, and improve patient outcomes.
Operating in the rapidly growing genomics market, Aevigenomics stands out by offering comprehensive genomic analysis services. This market is driven by the increasing demand for personalized medicine, where treatments are tailored to an individual's genetic makeup. By providing detailed genetic insights, Aevigenomics helps its clients make informed decisions, leading to more effective and efficient healthcare solutions.
The business model of Aevigenomics is based on a service-oriented approach. They offer genomic sequencing and analysis services on a subscription or per-project basis. This means clients either pay a recurring fee for ongoing access to their services or a one-time fee for specific projects. Additionally, Aevigenomics may partner with pharmaceutical companies for research and development projects, generating revenue through collaborative agreements.
Aevigenomics makes money by charging for its genomic analysis services. These services include sequencing DNA, interpreting genetic data, and providing detailed reports that help clients understand the genetic factors influencing health and disease. By offering high-quality, reliable data, Aevigenomics ensures that its clients can trust the insights they receive, which is crucial for making critical healthcare decisions.
In summary, Aevigenomics is a key player in the genomics market, providing essential services that enable personalized healthcare. Their business model focuses on delivering high-value genomic insights through a combination of subscription and project-based fees.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2011
News
Open roles
Aevi Genomic Medicine in its local ecosystem
The Aevi Genomic Medicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Alta Berkeley Venture Partners- KCKoor Corporate Venture Capital
Alta Partners
Series B and later1 investor entered at this stage
The Children's Hospital of Philadelphia
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aevi Genomic Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aevi Genomic Medicine on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

